Abubakr Akhtar Bajwa MD FCCP, DAABIP

Pulmonology•Jacksonville, FL

Interstitial Lung Diseases, Interventional Pulmonology, Pulmonary Vascular Medicine

Senior Associate Consultant, Associate Professor of Medicine

Join to View Full Profile

4500 San Pablo Rd SJacksonville, FL 32224
Phone+1 904-953-2000

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2007
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2005
University of South DakotaResidency, Internal Medicine, 2000 - 2003
King Edward Medical UniversityClass of 1998

Certifications & Licensure

FL State Medical License 2005 - 2027
MN State Medical License 2003 - 2005
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease
American Board of Internal Medicine Sleep Medicine
American Association of Bronchology and Interventional PulmonologyDiplomat American Association of Bronchology and Interventional Pulmonology
United Council for Neurologic SubspecialtiesNeuro Critical Care

Awards, Honors, & Recognition

Marquis Who's Who in Medicine 2012-2013
Marquis Who's Who 2011-2013

Clinical Trials

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis Start of enrollment: 2003 Aug 31
Completed
Phase 2
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPLETED
PHASE4
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
COMPLETED
PHASE3
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2010 Oct 01
Completed
Phase 3
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2011 Jun 01
Completed
Phase 3
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2012 Apr 01
Completed
Phase 2
Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching Start of enrollment: 2011 Nov 01
Terminated
Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1 Start of enrollment: 2012 Dec 01
Completed
Phase 1
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Respicardia, Inc. Pivotal Trial of the remedē System Start of enrollment: 2013 Mar 01
Completed
Not Applicable
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Beraprost-314d Added-on to Tyvaso® (BEAT) Start of enrollment: 2013 May 31
Completed
Phase 3
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Start of enrollment: 2017 Feb 03
Completed
Phase 2, Phase 3
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction Start of enrollment: 2017 Aug 15
Terminated
Phase 3
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF Start of enrollment: 2018 Jan 30
Terminated
Phase 3
ADAPT - a Patient Registry of the Real-world Use of Orenitram® Start of enrollment: 2017 Jul 18
ACTIVE_NOT_RECRUITING
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso Start of enrollment: 2019 Sep 17
COMPLETED
PHASE1
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) Start of enrollment: 2022 Nov 02
TERMINATED
PHASE3
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2021 Dec 02
TERMINATED
PHASE2, PHASE3
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Jun 01
ACTIVE_NOT_RECRUITING
PHASE3
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD Start of enrollment: 2021 Aug 01
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

31 citations
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
Aaron Waxman, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, Peter Engel, Abubakr Bajwa
The European Respiratory Journal. 2023-06-01
2 citations
Pleural Schwannoma Presenting As Musculoskeletal Type Pain: A Case Report.
Ali El-Husari, Hozaifa Tabbaa, Mohamed Ibrahim, Davong D Phrathep, Abubakr Bajwa
Cureus. 2023-04-01
15 citations
BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hyperten...
Leslie A Spikes, Abubakr A Bajwa, Charles D Burger, Sapna V Desai, Michael S Eggert
Pulmonary Circulation. 2022-04-01

Journal Articles

Characteristics and outcomes of cocaine related spontaneous intracerebral hemorrhages.
Bajwa AA, Silliman S, Cury JD, Jones LM, Shujaat A, Usman F, Samuel V, ISRN Neurology
A rare cause of hypoxia in a patient with liver cirrhosis
Girdhar A, Bajwa AA, Cury JD, Usman F, Resp Med Case Reports. 2012;6:5-6
12. Relationship between pulmonary artery hemodynamics and right ventricle function in pulmonary arterial hypertension using cardiovascular magnetic resonance
El-Sayed I, Bajwa AA, J Cardiovasc Magn Reson 2012, 14(Suppl 1):P82.
Approach to acute exacerbation of idiopathic pulmonary fibrosis
Bhatti M, Girdhar A, Usman A, Cury JD, Bajwa AA, Annals of Thoracic Medicine. 2013; 8 (2);71-77
Join now to see all